Zacks Investment Research on MSN

Vertex Plunges Around 24% in Six Months: How to Play the Stock

Vertex Pharmaceuticals Incorporated VRTX stock has declined 23.6% in the past six months, mainly due to recent pipeline ...
Zacks Investment Research on MSN

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals

Vertex Pharmaceuticals has a lot of buy and hold ratings, but there aren't any sell ratings from Wall Street analysts. Around ...

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years

Vertex Pharmaceuticals (VRTX) has outperformed the market over the past 15 years by 4.73% on an annualized basis producing an average annual return of 17.22%. Currently, Vertex Pharmaceuticals has a ...
The Motley Fool

If You Invested $5,000 in Vertex Pharmaceuticals in 2017, This Is How Much You Would Have Today

Vertex is defying the bear market, up 30% so far this year. The company is a leader in the cystic fibrosis market and generates billions of dollars annually from its treatments for that condition.
STAT

Vertex wins FDA approval for non-opioid pain drug, setting stage for closely watched rollout

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Vertex Pharmaceuticals on Thursday won approval from the Food and Drug ...